- Home
- VRAX vs RDHL Comparison
VRAX vs RDHL Comparison
Compare VRAX & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRAX | RDHL |
|---|---|---|
| Founded | 2013 | 2009 |
| Country | United Kingdom | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9M | 5.6M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | VRAX | RDHL |
|---|---|---|
| Price | $0.38 | $1.06 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 908.5K | 71.8K |
| Earning Date | 01-01-0001 | 09-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $2,986.00 | ★ $9,550,000.00 |
| Revenue This Year | $217,274.83 | $381.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 157.62 |
| 52 Week Low | $0.31 | $0.91 |
| 52 Week High | $3.20 | $6.80 |
Technical Indicators
Market Signals| Indicator | VRAX | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 44.43 | 38.43 |
| Support Level | $0.31 | $0.91 |
| Resistance Level | $0.51 | $1.23 |
| Average True Range (ATR) | 0.05 | 0.07 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 35.19 | 46.21 |
Price Performance
Historical ComparisonAbout VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.